In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


Credit Designation Statement

AACR has designated this internet live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking 7.0 AMA PRA Category 1 Credit(s)TM for this internet live continuing medical education activity must complete the online CME Request for Credit Survey by Wednesday, October 27, 2021. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Request for Credit Survey

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Printable List of CME-Designated Sessions

Statement of Educational Need, Target Audience, and Learning Objectives

Approximately 21,410 women will be diagnosed with ovarian cancer this year in the United States alone. Worldwide, there were over 313,000 new cases of ovarian cancer in 2020. The earlier that ovarian cancer is diagnosed, the better the 5-year survival rate. In fact, the 5-year survival rate for localized ovarian cancer is 92.6%; however, only 16% of ovarian cancers are diagnosed at this stage. About 57% of ovarian cancer cases are diagnosed at an advanced/distant stage (i.e. the cancer has metastasized), resulting in a much lower survival rate. These data call on the need for an improvement of early detection and identification of high-risk individuals to diagnose patients at the earliest stage possible and increase the likelihood of treatment success.

The treatment of ovarian cancer has expanded beyond first-line surgery, chemotherapy, and radiation due, in large part, to continued advancements in areas such as DNA damage/repair, immunology, the tumor microenvironment, and molecular drivers. It is critical to assess these basic research underpinnings that inform clinical therapeutics, as well as, discuss how observations from clinical practice can be back-translated into subsequent basic mechanistic research.

This conference will address and discuss all of these important needs in ovarian cancer research and treatment with sessions focusing on epidemiology and prevention, genetics, epigenetics, and cancer evolution, immunology, the tumor microenvironment, and DNA damage and replication stress.

After participating in this CME activity, physicians should be able to:

  1. Discuss factors of ovarian cancer risk and prevention.
  2. Demonstrate an understanding of ovarian cancer genetics, epigenetics, and evolution.
  3. Explore the biology of DNA damage and replication stress in ovarian cancer and its therapeutic implications.
  4. Explain current research in immunology and the role of the tumor environment in ovarian cancer.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the website of this conference.

Planner and Speaker Financial Disclosure Index

Acknowledgment of Financial or Other Support

The AACR gratefully acknowledges the following commercial supporters:

Professional Education Grants

AstraZeneca
GlaxoSmithKline
Merck
Novocure, Inc.

Questions about CME?

AACR Virtual Special Conference: Ovarian Cancer FAQ’s

Please contact the Office of CME at (215) 440-9300 or [email protected].